(Q33274853)

25 July 2017

1 reference

title

Functional outcomes of drug treatment in Alzheimer's disease: A systematic review and meta-analysis (English)

1 reference

25 July 2017

0 references

0 references

1 reference

2

1 reference

25 July 2017

Richard A Hansen

1

0 references

Kathleen Lohr

series ordinal

3

object named as

Kathleen N Lohr

1 reference

25 July 2017

Daniel I Kaufer

4

1 reference

25 July 2017

1 January 2007

1 reference

25 July 2017

1 reference

25 July 2017

24

1 reference

25 July 2017

2

1 reference

25 July 2017

155-167

1 reference

https://scigraph.springernature.com/pub.10.2165/00002512-200724020-00007

25 July 2017

0 references

cites work

Meta-analysis: principles and procedures

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200724020-00007

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200724020-00007

A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200724020-00007

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200724020-00007

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200724020-00007

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200724020-00007

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200724020-00007

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200724020-00007

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200724020-00007

21 January 2018

Memantine for dementia

1 reference

12 December 2020

Global prevalence of dementia: a Delphi consensus study

1 reference

12 December 2020

Longitudinal study on the relationship between symptomatology of dementia and levels of subjective burden and depression among family caregivers in memory clinic patients.

1 reference

12 December 2020

Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

1 reference

12 December 2020

A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease

1 reference

12 December 2020

Operating characteristics of a rank correlation test for publication bias

1 reference

12 December 2020

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting

1 reference

12 December 2020

Current methods of the US Preventive Services Task Force: a review of the process

1 reference

12 December 2020

Direction and impact of language bias in meta-analyses of controlled trials: empirical study.

1 reference

12 December 2020

Electrocardiographic effects of rivastigmine

1 reference

12 December 2020

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group

1 reference

12 December 2020

Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease

1 reference

12 December 2020

Donepezil for dementia due to Alzheimer's disease

1 reference

12 December 2020

Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial

1 reference

12 December 2020

The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group.

1 reference

12 December 2020

1 reference

12 December 2020

Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature

1 reference

12 December 2020

A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease

1 reference

12 December 2020

Evidence-based pharmacotherapy of Alzheimer's disease

1 reference

12 December 2020

Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group.

1 reference

12 December 2020

Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration

1 reference

12 December 2020

Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials

1 reference

12 December 2020

Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period

1 reference

12 December 2020

Memantine in moderate-to-severe Alzheimer's disease

1 reference

12 December 2020

Adverse effects associated with the use of donepezil in general practice in England.

1 reference

12 December 2020

Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease

1 reference

12 December 2020

Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.

1 reference

12 December 2020

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

1 reference

12 December 2020

A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease

1 reference

12 December 2020

Evidence of evidence-based health policy: the politics of systematic reviews in coverage decisions

1 reference

12 December 2020

10.2165/00002512-200724020-00007

Identifiers

DOI

1 reference

PubMed ID

17313203

Dimensions Publication ID

25 July 2017

0 references

1 reference

PubMed ID

17313203